Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.
Dalton Trans. 2021 Apr 7;50(13):4663-4672. doi: 10.1039/d0dt04135a. Epub 2021 Mar 16.
The Pt(iv) complexes based on (SP-4-2)-dichlorido(cyclohexane-1,4-diamine)platinum(ii) (kiteplatin) and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid (POA) were investigated. Since POA contains a chiral carbon, all the possible Pt(iv) isomers were prepared and characterized, and their antiproliferative activity on six cancer cell lines was compared with that of the corresponding Pt(iv) complexes containing the cyclohexane-1R,2R-diamine equatorial ligand. To justify the very good antiproliferative activity (nanomolar IC), the polarity, lipophilicity, permeability, and cell accumulation of the complexes were studied. Overall, the two series of Pt(iv) complexes showed similar cell penetration properties, being significantly better than that of the Pt(ii) reference compounds. Finally, a representative compound of the whole set of complexes (i.e., that based on cyclohexane-1R,2R-diamine and racemic POA) was tested in vivo on mice bearing Lewis lung carcinoma, showing good tumor growth inhibition with negligible body weight loss.
研究了基于(SP-4-2)-二氯(环己烷-1,4-二胺)铂(II)(kiteplatin)和组蛋白去乙酰化酶抑制剂 2-(2-丙炔基)辛酸(POA)的 Pt(iv) 配合物。由于 POA 含有一个手性碳原子,因此制备并表征了所有可能的 Pt(iv)异构体,并比较了它们对六种癌细胞系的增殖活性与含有环己烷-1R,2R-二胺赤道配体的相应 Pt(iv) 配合物的活性。为了证明其非常好的增殖抑制活性(纳摩尔 IC),研究了配合物的极性、亲脂性、通透性和细胞积累。总体而言,这两个系列的 Pt(iv) 配合物表现出相似的细胞穿透特性,明显优于 Pt(ii) 参考化合物。最后,在携带 Lewis 肺癌的小鼠体内对整个配合物系列中的一个代表性化合物(即基于环己烷-1R,2R-二胺和外消旋 POA 的化合物)进行了测试,结果表明该化合物具有良好的肿瘤生长抑制作用,而体重减轻可忽略不计。